XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1

REVENUE (Tables)

3 Months Ended

Jan. 31, 2024

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:

			Three Months Ended January 31,
			2024																								2023
			Life Sciences and Applied Markets						Agilent CrossLab						Diagnostics and Genomics						Total						Life Sciences and Applied Markets						Agilent CrossLab						Diagnostics and Genomics						Total
			(in millions)
Revenue by Region
Americas			$	244					$	164					$	222					$	630					$	286					$	154					$	247					$	687
Europe			224						111						123						458						239						98						119						456
Asia Pacific			378						130						62						570						418						129						66						613
Total			$	846					$	405					$	407					$	1,658					$	943					$	381					$	432					$	1,756

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:

									Three Months Ended
									January 31,
															2024						2023
												(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical															$	565					$	639
Chemicals and Advanced Materials															392						406
Diagnostics and Clinical															228						239
Food															157						160
Academia and Government															150						146
Environmental and Forensics															166						166
Total															$	1,658					$	1,756
Revenue by Type
Instrumentation															$	630					$	759
Non-instrumentation and other															1,028						997
Total															$	1,658					$	1,756

Contract Liabilities and Changes in Balances

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2024:

						Contract Liabilities
						(in millions)
Ending balance as of October 31, 2023						$	616
Net revenue deferred in the period						254
Revenue recognized that was included in the contract liability balance at the beginning of the period						(229)
Change in deferrals from customer cash advances, net of revenue recognized						(5)
Currency translation and other adjustments						8
Ending balance as of January 31, 2024						$	644

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration